Motor evoked potentials in multiple sclerosis patients without walking limitation: amplitude vs. conduction time abnormalities |
| |
Authors: | Andrea Gagliardo Francesca Galli Antonello Grippo Aldo Amantini Cristiana Martinelli Maria Pia Amato Walter Borsini |
| |
Affiliation: | (1) Clinical Neurophysiology Unit, Dept. of Neurological and Psychiatric Sciences, Careggi Hospital, University of Florence, V.le Morgagni, 85 50100 Florence, Italy;(2) Neurological Clinic II, Careggi Hospital, University of Florence, Florence, Italy;(3) Neurological Clinic I, Careggi Hospital, University of Florence, Florence, Italy |
| |
Abstract: | We used Motor Evoked Potentials (MEPs), elicited by transcranial magnetic stimulation, for assessing a motor pathways dysfunction in a selected group of Multiple Sclerosis (MS) patients, without limitation in walking. We selected 32 Relapsing Remitting MS patients, in remission phase, with EDSS ≤ 3.5 and 20 healthy individuals with similar height and age distribution. We measured the following MEP parameters: motor thresholds; central motor conduction time (CMCT); amplitude and area, both expressed as MEP/CMAP ratio. Patients were divided into two groups according to the EDSS score: non-disabled group (ND; EDSS 0–1.5) and disabled group (D; EDSS 2–3.5). Mean average MEP values were significantly different in the patients compared with the controls. Even in MS patients with no or minor neurological signs (ND group), MEP parameters showed differences from controls and furthermore all MEP parameters were significantly different in the D group compared with the ND group. The 75% of the patients had an amplitude or area alteration; this percentage was significantly higher than the percentage of patients with a CMCT alteration (56.2%). In addition, CMCT increase was always associated with reduced amplitude and area, but amplitude and area alterations were present also in patients with normal CMCT. In early stages of MS, the higher percentage shown in alteration of MEP amplitudes and areas as opposed to CMCTs has not previously been highlighted in the literature. Independently of its pathogenesis (demyelination or axonal loss), the amplitude or area decrease should be considered in clinical trials and in follow-up studies, as a marker of the motor pathways dysfunction, at least as much as CMCT increase. Received in revised form: 3 April 2006 |
| |
Keywords: | transcranial magnetic stimulation motor evoked potentials central motor conduction time multiple sclerosis |
本文献已被 PubMed SpringerLink 等数据库收录! |
|